Also known as: immunosuppressants
The FDA expanded efgartigimod approval to all adult generalized myasthenia gravis serotypes. Phase 3 ADAPT SERON met its primary endpoint and showed no new safety signals.
Johnson & Johnson said revenue could reach about $100.5 billion at the midpoint in 2026 after 2024 net sales rose 6% to $94.2 billion. The company faces talc litigation, Stelara patent losses and U.S. drug price negotiations.
Biogen announced that litifilimab received FDA Breakthrough Therapy Designation for cutaneous lupus erythematosus and will present Phase 2 AMETHYST study results at the 2026 AAD Annual Meeting, with Phase 3 data expected in 2027.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Phase 3 trials demonstrate atrasentan slows kidney function decline in IgA nephropathy patients, while obinutuzumab achieves superior remission rates in primary membranous nephropathy compared to standard treatment.
